Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin ophthalmic - Santen SAS

Next Previous
Drug Profile

Ciclosporin ophthalmic - Santen SAS

Alternative Names: Ciclosporin - Santen SAS; Cyclokat; Cyclosporin - Santen SAS; Cyclosporine Ophthalmic Emulsion - Santen S.A.S; DE 076B; DE 076C; Ikervis; Nova 22007; STN-1007603; Vekacia; Verkazia

Latest Information Update: 19 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novagali Pharma
  • Developer Santen Pharmaceutical; Santen S.A.S.
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Allergic conjunctivitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic conjunctivitis; Dry eyes

Most Recent Events

  • 16 Feb 2024 Apotex in-licenses exclusive rights for manufacturing and commercialization of ciclosporin ophthalmic from Harrow in Canada
  • 29 Sep 2023 Harrow Health is now called Harrow
  • 18 Jul 2023 Harrow Health in-licenses exclusive rights for manufacturing and commercialization of ciclosporin ophthalmic from Santen Pharmaceutical in the US and Canada
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top